3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Melatonin MT 1 and MT 2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Melatonin (MLT) is a neurohormone that regulates many physiological functions including sleep, pain, thermoregulation, and circadian rhythms. MLT acts mainly through two G-protein-coupled receptors named MT 1 and MT 2, but also through an MLT type-3 receptor (MT 3). However, the role of MLT receptor subtypes in thermoregulation is still unknown. We have thus investigated the effects of selective and non-selective MLT receptor agonists/antagonists on body temperature (T b) in rats across the 12/12-h light–dark cycle. Rectal temperature was measured every 15 min from 4:00 a.m. to 9:30 a.m. and from 4:00 p.m. to 9:30 p.m., following subcutaneous injection of each compound at either 5:00 a.m. or 5:00 p.m. MLT (40 mg/kg) had no effect when injected at 5 a.m., whereas it decreased T b during the light phase only when injected at 5:00 p.m. This effect was blocked by the selective MT 2 receptor antagonist 4P-PDOT and the non-selective MT 1/MT 2 receptor antagonist, luzindole, but not by the α 1/MT 3 receptors antagonist prazosin. However, unlike MLT, neither the selective MT 1 receptor partial agonist UCM871 (14 mg/kg) nor the selective MT 2 partial agonist UCM924 (40 mg/kg) altered T b during the light phase. In contrast, UCM871 injected at 5:00 p.m. increased T b at the beginning of the dark phase, whereas UCM924 injected at 5:00 a.m. decreased T b at the end of the dark phase. These effects were blocked by luzindole and 4P-PDOT, respectively. The MT 3 receptor agonist GR135531 (10 mg/kg) did not affect T b. These data suggest that the simultaneous activation of both MT 1 and MT 2 receptors is necessary to regulate T b during the light phase, whereas in a complex but yet unknown manner, they regulate T b differently during the dark phase. Overall, MT 1 and MT 2 receptors display complementary but also distinct roles in modulating circadian fluctuations of T b.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Melatonin: Physiological effects in humans.

          Melatonin is a methoxyindole synthesized and secreted principally by the pineal gland at night under normal light/dark conditions. The endogenous rhythm of secretion is generated by the suprachiasmatic nuclei and entrained to the light/dark cycle. Light is able to either suppress or synchronize melatonin production according to the light schedule. The nycthohemeral rhythm of this hormone can be evaluated by repeated measurement of plasma or saliva melatonin or urine sulfatoxymelatonin, the main hepatic metabolite. The primary physiological function of melatonin, whose secretion adjusts to night length, is to convey information concerning the daily cycle of light and darkness to body structures. This information is used for the organisation of functions, which respond to changes in the photoperiod such as the seasonal rhythms. Seasonal rhythmicity of physiological functions in humans related to possible alteration of the melatonin message remains, however, of limited evidence in temperate areas under field conditions. Also, the daily melatonin secretion, which is a very robust biochemical signal of night, can be used for the organisation of circadian rhythms. Although functions of this hormone in humans are mainly based on correlations between clinical observations and melatonin secretion, there is some evidence that melatonin stabilises and strengthens coupling of circadian rhythms, especially of core temperature and sleep-wake rhythms. The circadian organisation of other physiological functions depend also on the melatonin signal, for instance immune, antioxidant defences, haemostasis and glucose regulation. The difference between physiological and pharmacological effects of melatonin is not always clear but is based upon consideration of dose and not of duration of the hormone message. It is admitted that a "physiological" dose provides plasma melatonin levels in the same order of magnitude as a nocturnal peak. Since the regulating system of melatonin secretion is complex, following central and autonomic pathways, there are many pathophysiological situations where melatonin secretion can be disturbed. The resulting alteration could increase the predisposition to disease, add to the severity of symptoms or modify the course and outcome of the disorder. Since melatonin receptors display a very wide distribution in the body, putative therapeutic indications of this compound are multiple. Great advances in this field could be achieved by developing multicentre trials in a large series of patients, in order to establish efficacy of melatonin and absence of long-term toxicity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Melatonin as a chronobiotic.

            Melatonin, hormone of the pineal gland, is concerned with biological timing. It is secreted at night in all species and in ourselves is thereby associated with sleep, lowered core body temperature, and other night time events. The period of melatonin secretion has been described as 'biological night'. Its main function in mammals is to 'transduce' information about the length of the night, for the organisation of daylength dependent changes, such as reproductive competence. Exogenous melatonin has acute sleepiness-inducing and temperature-lowering effects during 'biological daytime', and when suitably timed (it is most effective around dusk and dawn) it will shift the phase of the human circadian clock (sleep, endogenous melatonin, core body temperature, cortisol) to earlier (advance phase shift) or later (delay phase shift) times. The shifts induced are sufficient to synchronise to 24 h most blind subjects suffering from non-24 h sleep-wake disorder, with consequent benefits for sleep. Successful use of melatonin's chronobiotic properties has been reported in other sleep disorders associated with abnormal timing of the circadian system: jetlag, shiftwork, delayed sleep phase syndrome, some sleep problems of the elderly. No long-term safety data exist, and the optimum dose and formulation for any application remains to be clarified.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A hypothalamic circuit that controls body temperature.

              The homeostatic control of body temperature is essential for survival in mammals and is known to be regulated in part by temperature-sensitive neurons in the hypothalamus. However, the specific neural pathways and corresponding neural populations have not been fully elucidated. To identify these pathways, we used cFos staining to identify neurons that are activated by a thermal challenge and found induced expression in subsets of neurons within the ventral part of the lateral preoptic nucleus (vLPO) and the dorsal part of the dorsomedial hypothalamus (DMD). Activation of GABAergic neurons in the vLPO using optogenetics reduced body temperature, along with a decrease in physical activity. Optogenetic inhibition of these neurons resulted in fever-level hyperthermia. These GABAergic neurons project from the vLPO to the DMD and optogenetic stimulation of the nerve terminals in the DMD also reduced body temperature and activity. Electrophysiological recording revealed that the vLPO GABAergic neurons suppressed neural activity in DMD neurons, and fiber photometry of calcium transients revealed that DMD neurons were activated by cold. Accordingly, activation of DMD neurons using designer receptors exclusively activated by designer drugs (DREADDs) or optogenetics increased body temperature with a strong increase in energy expenditure and activity. Finally, optogenetic inhibition of DMD neurons triggered hypothermia, similar to stimulation of the GABAergic neurons in the vLPO. Thus, vLPO GABAergic neurons suppressed the thermogenic effect of DMD neurons. In aggregate, our data identify vLPO→DMD neural pathways that reduce core temperature in response to a thermal challenge, and we show that outputs from the DMD can induce activity-induced thermogenesis.
                Bookmark

                Author and article information

                Journal
                Int J Mol Sci
                Int J Mol Sci
                ijms
                International Journal of Molecular Sciences
                MDPI
                1422-0067
                17 May 2019
                May 2019
                : 20
                : 10
                : 2452
                Affiliations
                [1 ]Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University Health Center (MUHC), McGill University, Montreal, QC H3A1A1, Canada; martha.lopezcanul@ 123456mcgill.ca (M.L.-C.); seung.min@ 123456mail.mcgill.ca (S.H.M.); luca.posa@ 123456mail.mcgill.ca (L.P.); danilo.degregorio@ 123456mail.mcgill.ca (D.D.G.); comai.stefano@ 123456hsr.it (S.C.)
                [2 ]Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC H3A 0G1, Canada
                [3 ]Department of Biomolecular Sciences, University Carlo Bo, 61029 Urbino, Italy; annalida.bedini@ 123456uniurb.it (A.B.); gilberto.spadoni@ 123456uniurb.it (G.S.)
                [4 ]Neuropsychopharmacology Unit, San Raffaele Scientific Institute and Vita-Salute University, 20132 Milan, Italy
                Author notes
                [* ]Correspondence: gabriella.gobbi@ 123456mcgill.ca ; Tel.: +1-514-398-1290
                [†]

                These authors contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-6464-1961
                https://orcid.org/0000-0002-5686-7194
                Article
                ijms-20-02452
                10.3390/ijms20102452
                6566544
                31108968
                bf0186b9-1b30-457f-8b9b-31d1f92a89b9
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 15 April 2019
                : 10 May 2019
                Categories
                Article

                Molecular biology
                melatonin,mt1 receptors,mt2 receptors,mt3 receptors,body temperature,light/dark cycle

                Comments

                Comment on this article